Genmab — Maj 2020
-
And we will not actually let the coronavirus troubles hinder that because we actually think that we can turn this era into an advantage potentially for Genmab and for the partner for epcoritamab because we know that some of the large Phase III trials from competing programs like the Roche CD20 -- CD3/CD20 bispecific programs are on hold right now, whereas we are still recruiting patients and planning new studies
-
Så blev vi så meget klogere på hjemmeadministration. :-). Sikkert fremprovokeret af covid 19. Det er bedre at sende en sygeplejerske ud, som er erfaren med beskyttelse, end at få en potentiel smittebærer ind. Og det er jo ikke sikkert, at det vil foregå hjemme allerede fra 1. injektion pga observation.
-
gentogen, 09:00 - ikke for så vidt angår epcoritamab i hvert fald: "And what is also good, Michael, is that despite the challenges, of course, of recruiting patients in this COVID-19 era, I can tell you that the doctors have been very, very enthusiastic about moving patients into this study, this Phase I/II study."
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind